Sofinnova Partners — 2023 Investments
7 investments dated 2023 · listed companies and verified rows first · show all
BioCorteX develops personalized therapeutics using a microbiome knowledge graph and proprietary biology emulation platform to tailor drug treatments for diverse populations.
AI & Machine LearningBiotechDigital HealthMedical Devices
Co-investorsHoxton VenturesDraper Associates
Alia Therapeutics is a biotech company developing therapeutics based on gene-editing technology.
BiotechDeep TechHealthtech
Co-investorsIndaco Venture Partners
CorVent Medical develops medical ventilators, including the RESPOND ventilator, that provide ICU-standard respiratory support for acute and post-acute patients.
HardwareHealthtechMedical DevicesFargo, US
Murphy Travis(Executive Officer)Jeremy Nelson(Executive Officer)Richard S. Walsh(Executive Officer, Director)John O'Mahony(Executive Officer)Rob Faulkner(Director)Lukas Geunther(Director)
Crescendo Biologics develops T cell enhancing therapeutics for immuno-oncology, based on its Humabody platform, with clinical candidates including the bispecific CB307 and immune cell engager CB699.
BiotechHealthtech
Co-investorsAndera PartnersAstellas Venture Management LLCEMBL VenturesFuture Planet CapitalQuan CapitalAvlar BioVentures+1 more
Princeton, US
Dylan Porges(Mr. Porges is a Director.)Ayooluwa Oguntola(Mr. Oguntola is CEO and a Director.)
Mozart Therapeutics develops protein therapeutics focused on immunology and oncology treatments.
BiotechMedical Devices
Mark Davis(Scientific Co-Founder)K. Christopher Garcia(Scientific Co-Founder)Calvin Kuo(Scientific Co-Founder)Katie Fanning(President & Chief Executive Officer)
Co-investorsARCH Venture PartnersJDRF T1D FundMRL Ventures FundOno Venture Investment, Inc.Pfizer Venture InvestmentsAlexandria+3 more
Women-led biotech company engineering high-performance protein-based textile fibers for fashion with sustainable alternatives to synthetic fibers.
BiotechBrooklyn, US
Valentina Gomez(Executive Officer, Director)Theanne Schiros(Executive Officer)Chui-lian Lee(Executive Officer, Director)Chui-Lian Lee(Founder)in
BoardCorinna Chen(Director)inMichael Krel(Director)in
Co-investorsMaterial Impact
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.